How effective is temozolomide for treating pituitary tumours and when should it be used?

Is there a role for early chemotherapy in the management of pituitary adenomas?

(2016) Andrew L. Lin et al.   NEURO-ONCOLOGY

Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide

(2015) Daniel Bengtsson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The role of temozolomide in the treatment of aggressive pituitary tumors

(2015) James K. Liu et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center

(2015) Filippo Ceccato et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas

(2015) Marco Losa et al.   JOURNAL OF NEURO-ONCOLOGY

Aggressive Pituitary Tumors

(2015) Eleftherios Chatzellis et al.   NEUROENDOCRINOLOGY

Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment

(2015) Mariana Campderá et al.   Pituitary

Novel MSH6 Mutations in Treatment-Naive Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

(2014) S. A. Nguyen et al.   CLINICAL CANCER RESEARCH

Aggressive pituitary adenomas—diagnosis and emerging treatments

(2014) Antonio Di Ieva et al.   Nature Reviews Endocrinology

DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors

(2013) Toshio Hirohata et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide in the management of dopamine agonist-resistant prolactinomas

(2012) B. C. Whitelaw et al.   CLINICAL ENDOCRINOLOGY

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

(2012) Gérald Raverot et al.   CLINICAL ENDOCRINOLOGY

Temozolomide in aggressive pituitary adenomas and carcinomas

(2012) LD Ortiz et al.   Clinics

Treatment of pituitary neoplasms with temozolomide

(2011) Gianluca Marucci   CANCER

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

(2011) Ann I. McCormack et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas

(2011) Fateme Salehi et al.   JOURNAL OF NEURO-ONCOLOGY

A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report

(2011) Mineko Murakami et al.   NEUROSURGERY

Treatment of pituitary neoplasms with temozolomide

(2010) Luis V. Syro et al.   CANCER

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

(2010) Marco Losa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases

(2010) H. Bode et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

(2010) Zachary M. Bush et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

(2010) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

(2009) Jennifer A. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of Disease: temozolomide and glioblastoma—look to the future

(2008) Maciej M Mrugala et al.   Nature clinical practice. Oncology